Meropenem – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:11 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Meropenem – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Meropenem Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-meropenem-market-2021-2025/ Fri, 23 Apr 2021 13:03:00 +0000 https://www.cri-report.com/?post_type=product&p=11194 According to CRI's market research, the sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, the sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year.

The post Investigation Report on China’s Meropenem Market 2021-2025 first appeared on CRI Report.

]]> Meropenem is an antibiotic that is used to treat a variety of bacterial infections, including meningitis, pneumonia and so on. Meropenem is jointly developed by Sumitomo Dainippon Pharma and Imperial Chemical Industries (ICI). It was launched in the Chinese market in 1999. Currently, besides Sumitomo Dainippon Pharma, the other main manufacturers in the Chinese market are Shenzhen Haibin Pharmaceutical, CSPC Ouyi Pharmaceutical Group, Hanhui Pharmaceuticals, and Haikou Pharmaceutical Factory.

According to CRI’s market research, the sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, the sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year. The main reason is that the COVID-19 epidemic has impacted the hospitals’ overall operation. The CAGR of sales value of Meropenem in China is 2% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Meropenem will have a recovery growth from 2021 to 2025. In addition, the strict limits on the usage of antibiotic drugs and the emergence of drug resistance have driven the demand for more effective antibacterial drugs. Therefore, Meropenem, as a new generation of antibacterial drugs, has the potential to expand its sales in the future.

Topics Covered:
-The impact of COVID-19 on China’s Meropenem market
– Sales value and volume of China’s Meropenem 2016-2020
– Competitive landscape of China’s Meropenem market
– Prices of Meropenem in China
– Prices of Meropenem in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Meropenem market
– Prospect of China’s Meropenem market from 2021 to 2025

The post Investigation Report on China’s Meropenem Market 2021-2025 first appeared on CRI Report.

]]>